Skip to content
AnalystLens

Illumina 8-K Report, Financial Results (Oct 29, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 29, 2026
Period End
October 29, 2026
Security
ILMN
In the record · 2016–202610-K1110-Q338-K167

ILMN filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 167 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Feb ’17Feb ’17
  2. Material agreement8-K · Sep ’19Sep ’19
  3. Deal closed8-K · Oct ’21Oct ’21
  4. Leadership change8-K · Jan ’26Jan ’26

01—Abstract

Summary

Summary of the 8-K filed October 29, 2026. Cited figures are marked; the original filing is the authoritative source.

Illumina, Inc. reported third quarter 2026 results for the quarter ended September 27, 2026, in a press release furnished as Exhibit 99.1 to this Form 8-K.

Reported revenue was $1.13 billiona, up 4.2% from Q3 2025, and revenue excluding tariff refunds was $1.17 billion, up 4.7% on the company's ROW1 organic revenue growth basis. GAAP operating margin was 27.0% and GAAP diluted EPS was $1.43, compared with 21.0% and $0.98 in the prior-year quarter. Non-GAAP operating margin excluding tariff refunds was 25.0%, and non-GAAP diluted EPS excluding tariff refunds was $1.44.

The results include an IEEPA tariff refund benefit of $79 millionb recognized as a reduction to cost of revenue, partly offset by a $37 million reduction to revenue for the portion expected to be credited to customers. Management raised full-year 2026 guidance, excluding tariff refunds. Total revenue is now expected at $4.64-$4.66 billion, up from $4.60-$4.64 billion, and non-GAAP diluted EPS is now expected at $5.40-$5.45, up from $5.30-$5.40.

Non-GAAP operating margin guidance moved to 23.6%c from a prior range of 23.4%-23.6%. Organic revenue growth guidance of greater than 4% and ROW organic revenue growth guidance of greater than 5% were unchanged. CEO Jacob Thaysen attributed the quarter's results above guidance to healthy clinical demand and robust NovaSeq X placements.

Cash flow from operations was $419 milliond for the quarter, compared with $284 million a year earlier, and free cash flow was $378 million, compared with $253 million. The company held $1.34 billion in cash, cash equivalents and short-term investments at quarter end. Total term debt on the balance sheet was $1.79 billion (non-current) at September 27, 2026, with no current portion, versus $1.49 billion non-current and $499 million current at fiscal year-end 2025.

02—Key points

Key Highlights

  1. Q3 2026 revenue of $1.13 billion, up 4.2% from Q3 2025; revenue excluding tariff refunds of $1.17 billion, up 4.7% on a ROW1 organic basis
  2. GAAP diluted EPS of $1.43 versus $0.98 a year earlier; non-GAAP diluted EPS excluding tariff refunds of $1.44 versus $1.34
  3. Q3 2026 includes a $79 million tariff refund benefit in cost of revenue, partly offset by a $37 million reduction to revenue for amounts expected to be credited to customers
  4. Full-year 2026 revenue guidance raised to $4.64-$4.66 billion (from $4.60-$4.64 billion) and non-GAAP EPS guidance raised to $5.40-$5.45 (from $5.30-$5.40), excluding tariff refunds
  5. Free cash flow of $378 million in Q3 2026 versus $253 million in Q3 2025; nine-month free cash flow of $791 million
  6. Cash, cash equivalents and short-term investments of $1.34 billion at quarter end
  7. Non-GAAP operating margin guidance of 23.6% for fiscal 2026, within the prior range, with organic growth guidance unchanged

03—Questions

Frequently Asked Questions

  1. How did Illumina perform in the third quarter of 2026?

    Reported revenue was $1.13 billion, up 4.2% from the prior year. GAAP operating margin was 27.0% and GAAP diluted EPS was $1.43. Excluding tariff refunds, revenue was $1.17 billion and non-GAAP operating margin was 25.0%.

  2. What did Illumina change in its full-year 2026 guidance?

    Total revenue guidance was raised to $4.64-$4.66 billion from $4.60-$4.64 billion, and non-GAAP diluted EPS guidance was raised to $5.40-$5.45 from $5.30-$5.40. Non-GAAP operating margin guidance moved to 23.6% from 23.4%-23.6%. Organic and ROW organic revenue growth guidance was unchanged. All guidance excludes tariff refunds.

  3. How much did tariff refunds affect third-quarter results?

    Tariff refunds under IEEPA included a $79 million benefit recognized as a reduction to cost of revenue and a $37 million reduction to revenue for the portion expected to be credited to customers. Excluding these impacts, GAAP-to-non-GAAP diluted EPS was $1.44 versus $1.62 including them.

  4. What was Illumina's cash flow and liquidity position?

    Cash flow from operations was $419 million in Q3 2026, compared with $284 million a year earlier, and free cash flow was $378 million. The company held $1.34 billion in cash, cash equivalents and short-term investments at quarter end.

  5. What drove the quarter's results according to management?

    CEO Jacob Thaysen said healthy clinical demand and robust NovaSeq X placements drove results above guidance, and cited the company's innovation and AI-related foundation work as broadening the value of its ecosystem.

04—Continue

← View all 8-K filings